SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3385)12/20/1997 1:51:00 PM
From: margie  Read Replies (1) | Respond to of 6136
 
continued from above:

Then comments that "But is that so great? Merck and Agouron have data from similar studies from out to two years. And 500 copies isn't that low, anymore." (I think Vertex use an assay with lower levels?) Then Eisenberg says there are continued concerns about the PI market, as November prescription data was weak, in his words, "but it was a short month."
Vertex ended the week at 36, pretty impressive.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News